Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
Per the terms, Otsuka will acquire exclusive rights to market its investigational late-stage hereditary angioedema (HAE) therapy, donidalorsen, in the Asia-Pacific region. This agreement is an expansion of the licensing deal signed last year. Per the terms, Ionis granted exclusive grants to Otsuka to market donidalorsen in Europe. With these deals, Otsuka will be responsible for territory-specific development, regulatory filings and commercialization activities for donidalorsen across the Asia-Pacific region and Europe. Ionis will continue to maintain responsibility for the non-clinical and clinical development of the drug. In consideration of granting the rights in the Asia-Pacific region, Ionis will receive an upfront payment of $20 million and will also be eligible for milestone payments. The company will also be eligible to receive tiered royalties on the drug's net sales, with terms similar to the previously-signed agreement for Europe (ranging from 20-30%). A rare geneti
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- She's fighting to stop the brain disease that killed her mother before it gets her. [USA TODAY]USA TODAY
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Stifel Nicolaus from $50.00 to $53.00. They now have a "hold" rating on the stock.MarketBeat
- FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
- Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 5/7/24 - Beat
IONS
Sec Filings
- 6/20/24 - Form 4
- 6/18/24 - Form 8-K
- 6/17/24 - Form 144
- IONS's page on the SEC website